Pfizer has an excellent heritage in endocrinology and remains highly committed to its endocrine product portfolio. Our portfolio includes treatments for acromegaly and growth hormone deficiency as part of our focus on rare disease

 

PP-UNP-IRL-0033  Date of Preparation: March 2022